Clinical benefit and safety profile of darolutamide in patients who crossed over to darolutamide from placebo during the open-label period of the phase 3 ARAMIS study

S. Feyerabend, N. Shore, M. Smith, E. Kopyltsov, I. Antonyan, J. Damber, D. Gasparro, A. Yildirim, M. Hellstrom, E. Vjaters, J. Ortiz, S. Srinivasan, T. Sarapohja, K. Fizazi

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Article numberP1227
Pages (from-to)S1742-S1743
Number of pages2
JournalEuropean Urology
Issue numberSupplement 1
Publication statusPublished - Jun 2021
Externally publishedYes
Event36th Annual European Association of Urology (EAU) Congress - Virtual
Duration: 8 Jul 202113 Jul 2021
Conference number: 36

Field of Science*

  • 3.2 Clinical medicine
  • 3.1 Basic medicine

Publication Type*

  • 3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Cite this